ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators: University of Wisconsin, Madison
National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00052832
  Purpose

RATIONALE: Doxercalciferol may improve low blood cell counts and decrease the need for blood transfusions and may be an effective treatment for myelodysplastic syndrome or chronic myelomonocytic leukemia.

PURPOSE: Phase II trial to study the effectiveness of doxercalciferol in treating patients who have myelodysplastic syndrome or chronic myelomonocytic leukemia.


Condition Intervention Phase
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Drug: doxercalciferol
Phase II

MedlinePlus related topics:   Leukemia, Adult Acute    Leukemia, Adult Chronic   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Open Label
Official Title:   Phase II Study of Doxercalciferol for the Treatment of Myelodysplastic Syndromes

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:   September 2002

Detailed Description:

OBJECTIVES:

  • Determine the response rate of patients with myelodysplastic syndromes or chronic myelomonocytic leukemia treated with doxercalciferol.
  • Determine the toxicity profile of this drug in these patients.
  • Determine the time to progression and overall survival of patients treated with this drug.

OUTLINE: Patients receive oral doxercalciferol daily for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: Approximately 41 patients will be accrued for this study.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Morphologically and cytogenetically confirmed myelodysplastic syndromes or chronic myelomonocytic leukemia

    • No more than 20% blasts by bone marrow biopsy
  • Must meet at least 1 of the following criteria:

    • Anemia

      • Hemoglobin less than 11 g/dL over a 2-month period
    • Thrombocytopenia
    • Neutropenia

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • See Disease Characteristics

Hepatic

  • ALT and AST less than 1.5 times upper limit of normal
  • Bilirubin less than 3 mg/dL
  • Albumin greater than 3.0 g/dL

Renal

  • Creatinine clearance greater than 50 mL/min
  • No history of hypercalcemia
  • No renal stones within the past 5 years

Cardiovascular

  • No clinically significant heart failure
  • No uncontrolled hypertension

Pulmonary

  • No clinically significant pulmonary failure

Other

  • Not pregnant
  • Fertile patients must use effective contraception during and for 6 months after study

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 4 weeks since prior growth factor or cytokine therapy

Chemotherapy

  • At least 8 weeks since prior cytotoxic chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • Concurrent transfusion support allowed
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00052832

Locations
United States, Wisconsin
University of Wisconsin Comprehensive Cancer Center    
      Madison, Wisconsin, United States, 53792

Sponsors and Collaborators
University of Wisconsin, Madison
National Cancer Institute (NCI)

Investigators
Study Chair:     Mark B. Juckett, MD     University of Wisconsin, Madison    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Publications of Results:

Study ID Numbers:   CDR0000258754, WCCC-HO-02403
First Received:   January 24, 2003
Last Updated:   July 23, 2008
ClinicalTrials.gov Identifier:   NCT00052832
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
chronic myelomonocytic leukemia  
previously treated myelodysplastic syndromes  
secondary myelodysplastic syndromes  
de novo myelodysplastic syndromes
atypical chronic myeloid leukemia
myelodysplastic/myeloproliferative disease, unclassifiable

Study placed in the following topic categories:
Myelodysplastic syndromes
Chronic myelogenous leukemia
Precancerous Conditions
Chronic myelomonocytic leukemia
Hematologic Diseases
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Myelodysplasia
Myelodysplastic Syndromes
Ergocalciferols
Myeloproliferative Disorders
Leukemia, Myeloid
Myelodysplastic myeloproliferative disease
Leukemia
Preleukemia
Vitamin D
1 alpha-hydroxyergocalciferol
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasm Metastasis
Myelodysplastic-Myeloproliferative Diseases
Bone Marrow Diseases

Additional relevant MeSH terms:
Neoplasms
Pathologic Processes
Disease
Neoplasms by Histologic Type
Growth Substances
Vitamins
Syndrome
Physiological Effects of Drugs
Bone Density Conservation Agents
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers